One Global Service Provider revised the pricing and number of shares for its preferential equity issuance to acquire controlling stakes in two healthcare entities. The board approved the changes on September 18, 2026, to comply with SEBI ICDR Regulations while keeping the total acquisition cost fixed.

The company will issue 7,06,068 fully paid-up equity shares with a face value of ₹10 each. The transaction involves acquiring a 51% stake in Matrix Labs Diagnocare Private Limited (MLDPL) and a 51% stake in Matrix Labs Private Limited (MLPL). The consideration is payable entirely through the issuance of these shares, meaning no cash outflow is required from One Global Service Provider for the purchase.

Revised Pricing Structure

The Board amended the Share Purchase Agreements (SPAs) to reflect new issue prices determined under Chapter V of the SEBI (ICDR) Regulations. The aggregate non-cash consideration for both deals remains unchanged from the initial agreements dated September 3, 2026.

The shares for MLDPL are allotted to Mr. Suresh and Ms. Nithya S, while the shares for MLPL are allotted to Mr. Suresh. The premium per share is ₹550.13 for MLDPL and ₹548.99 for MLPL.

Strategic Expansion in Healthcare

The acquisitions aim to strengthen One Global Service Provider’s presence in the diagnostic, pathology, and allied healthcare services sector. The addendums confirm that no special rights, such as director appointments or restrictions on capital structure changes, are granted to the sellers. The company stated that these amendments do not adversely impact its business or operations.

What the Numbers Show

The total value of the combined acquisitions stands at ₹39,54,17,120. By utilizing a non-cash consideration model, One Global Service Provider preserves its cash reserves while expanding its asset base. The slight variance in issue prices between the two entities (₹560.13 vs ₹558.99) reflects specific valuation adjustments for each target company’s share capital structure.

One Global Service Provider has scheduled its 34th Annual General Meeting (AGM) for September 29, 2026, to approve a final dividend of ₹1 per share for FY26 and sanction a major strategic acquisition via a preferential issue. The meeting will also seek shareholder consent for significant related-party transactions and enhanced borrowing limits.

Financial Performance and Dividend

The company reported a robust financial performance for FY26, driven by the amalgamation of Plus Care Internationals Private Limited. Total revenue surged to ₹49,881.06 lakh, up from ₹14,784.17 lakh in FY25. Profit after tax (PAT) more than tripled to ₹6,950.42 lakh from ₹1,846.66 lakh in the previous year.

The Board of Directors has recommended a final dividend of ₹1 per equity share (face value ₹10), representing a 10% payout. This is subject to shareholder approval at the AGM. The record date for both the dividend payment and voting eligibility is September 22, 2026.

Strategic Acquisition and Preferential Issue

A key agenda item is the proposed acquisition of a 51% stake in Matrix Labs Diagnocare Private Limited (MLDPL) and Matrix Labs Private Limited (MLPL). To facilitate this, the company plans to issue 7,15,040 equity shares on a preferential basis for consideration other than cash.

The issue price is set at ₹553 per share, based on the volume-weighted average price over the 10 trading days preceding the relevant date of August 28, 2026. The total non-cash consideration amounts to approximately ₹39.54 crore. The allottees include Mr. Suresh and Ms. Nithya S for MLDPL, and Mr. Suresh for MLPL.

Related Party Transactions and Borrowing Limits

The AGM will also approve material related-party transactions with Lifenity Health Limited (LHL), where the Managing Director serves as a non-executive director. The proposed transaction limit is ₹500 crore for FY27, covering the purchase and sale of goods, services, and assets. In FY26, sales to LHL totaled ₹16,321.21 lakh.

Additionally, shareholders are asked to approve:

• An increase in authorized share capital from ₹25.05 crore to ₹50 crore.
• Overall borrowing limits under Section 180(1)(c) of the Companies Act, 2013, up to the aggregate of paid-up capital, free reserves, and securities premium or ₹1,000 crore, whichever is higher.
• Re-appointment of Mr. Sanjay Upadhaya as Managing Director and M/s. S D P M & Co. as Statutory Auditors for a second five-year term.

What the Numbers Show

The dramatic expansion in revenue and PAT underscores the impact of the Plus Care Internationals merger. However, trade receivables have risen sharply to ₹21,657.79 lakh from ₹5,406.14 lakh in FY25, while cash and cash equivalents declined to ₹1,570.63 lakh from ₹2,714.72 lakh. This divergence suggests that while top-line growth is strong, working capital management and collection cycles will be critical areas to monitor as the company scales its operations through new acquisitions.